Breaking News, Financial News

Financial Report: Baxter

Revenues up 3% in the quarter

Baxter
 
2Q Revenues: $3.7 billion (+3%)

2Q Earnings: $590 million (-11%)

YTD Revenues: $7.1 billion (+2%)

YTD Earnings: $1.1 billion (-9%)

Comments: BioScience revenues were $1.6 billion in the quarter (+5%), driven by hemophilia therapies ADVATE and FEIBA, as well as specialty plasma-based therapeutics and vaccines. Medical Products sales were $2.0 billion (+1%). Second quarter results include after-tax special items totaling $49 million, primarily for costs associated the planned acquisition of Gambro AB.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters